Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction

The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone. Platelets express several members of the MAPK signalling cascade including MEK1 and MEK2 and ERK1 and ERK2 but t...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Platelets
Autori principali: Unsworth, Amanda J., Bye, Alexander P., Kriek, Neline, Sage, Tanya, Osborne, Ashley A., Donaghy, Dillon, Gibbins, Jonathan M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2018
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6594423/
https://ncbi.nlm.nih.gov/pubmed/30252580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/09537104.2018.1514107
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi